ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Many patients experience persistent tachycardia with episodes of rapid ventricular rate
despite chronic treatment to reduce ventricular rate. The objectives of this study are to
demonstrate the superiority of a nasal spray of etripamil over placebo, in reducing
ventricular rate in patients with atrial fibrillation; and to evaluate the safety and
efficacy of etripamil Nasal Spray in patients with atrial fibrillation (AF).
Phase:
Phase 2
Details
Lead Sponsor:
Milestone Pharmaceuticals Inc.
Collaborators:
APCER Life Sciences The Montreal Health Innovations Coordinating Center (MHICC)